Advertisement

In the Battle Between Protons and Photons for Hematologic Malignancies, the Patient Must Win

      The recent reintroduction of heavy charged particles into therapeutic radiation oncology has rekindled interest in such therapy, particularly with protons, and resulted in an unprecedented increase in the number of proton treatment centers in the United States. Subsequently, despite the higher cost of treatment with protons compared with available nonparticle therapy, the application of proton therapy to every oncologic site has been suggested and debated, to the point where those “for” and “against” protons have held debates in which each side strongly argued their beliefs.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hancock S.L.
        • Tucker M.A.
        • Hoppe R.T.
        Breast cancer after treatment of Hodgkin’s disease.
        J Natl Cancer Inst. 1993; 85: 25-31
        • Hancock E.W.
        Intermittent slow pulse in acute myocardial infarction.
        Hosp Pract (Off Ed). 1993; 28 (25, 28)
        • Aleman B.M.
        • van den Belt-Dusebout A.W.
        • Klokman W.J.
        • et al.
        Long-term cause-specific mortality of patients treated for Hodgkin’s disease.
        J Clin Oncol. 2003; 21: 3431-3439
        • Hodgson D.C.
        • Koh E.S.
        • Tran T.H.
        • et al.
        Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma.
        Cancer. 2007; 110: 2576-2586
        • Raemaekers J.M.
        • Andre M.P.
        • Federico M.
        • et al.
        Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
        J Clin Oncol. 2014; 32: 1188-1194
        • Radford J.
        • Illidge T.
        • Counsell N.
        • et al.
        Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma.
        N Engl J Med. 2015; 372: 1598-1607
        • Parikh R.R.
        • Grossbard M.L.
        • Harrison L.B.
        • et al.
        Impact of delays in definitive treatment on overall survival: A National Cancer Database study of patients with Hodgkin lymphoma.
        Leuk Lymphoma. 2015; : 1-25
        • Parikh R.R.
        • Grossbard M.L.
        • Harrison L.B.
        • et al.
        Early-stage classic Hodgkin lymphoma: The utilization of radiation therapy and its impact on overall survival.
        Int J Radiat Oncol Biol Phys. 2015; 93: 684-693
        • Olszewski A.J.
        • Shrestha R.
        • Castillo J.J.
        Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: Analysis of the National Cancer Data Base.
        J Clin Oncol. 2015; 33: 625-633
        • Koh E.S.
        • Tran T.H.
        • Heydarian M.
        • et al.
        A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: Reduction in normal tissue dose and second cancer risk.
        Radiat Oncol. 2007; 2: 13
        • Koontz B.F.
        • Kirkpatrick J.P.
        • Clough R.W.
        • et al.
        Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin’s disease: Cure balanced against complications.
        J Clin Oncol. 2006; 24: 605-611
        • Girinsky T.
        • van der Maazen R.
        • Specht L.
        • et al.
        Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines.
        Radiother Oncol. 2006; 79: 270-277
        • Specht L.
        • Yahalom J.
        • Illidge T.
        • et al.
        Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG).
        Int J Radiat Oncol Biol Phys. 2014; 89: 854-862
        • Illidge T.
        • Specht L.
        • Yahalom J.
        • et al.
        Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group.
        Int J Radiat Oncol Biol Phys. 2014; 89: 49-58
        • Dabaja B.S.
        • Rebueno N.C.
        • Mazloom A.
        • et al.
        Radiation for Hodgkin’s lymphoma in young female patients: A new technique to avoid the breasts and decrease the dose to the heart.
        Int J Radiat Oncol Biol Phys. 2011; 79: 503-507
        • Pedersen A.N.
        • Korreman S.
        • Nystrom H.
        • et al.
        Breathing adapted radiotherapy of breast cancer: Reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold.
        Radiother Oncol. 2004; 72: 53-60
        • Voong K.R.
        • McSpadden K.
        • Pinnix C.C.
        • et al.
        Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma.
        Radiat Oncol. 2014; 9: 94
        • Filippi A.R.
        • Ragona R.
        • Piva C.
        • et al.
        Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: A comparison of second cancers and heart disease risk.
        Int J Radiat Oncol Biol Phys. 2015; 92: 161-168
        • Pinnix C.C.
        • Smith G.L.
        • Milgrom S.
        • et al.
        Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.
        Int J Radiat Oncol Biol Phys. 2015; 92: 175-182
        • Guan F.
        • Bronk L.
        • Titt U.
        • et al.
        Spatial mapping of the biologic effectiveness of scanned particle beams: Towards biologically optimized particle therapy.
        Sci Rep. 2015; 5: 9850
        • Paganetti H.
        Relating proton treatments to photon treatments via the relative biological effectiveness—should we revise current clinical practice?.
        Int J Radiat Oncol Biol Phys. 2015; 91: 892-894
        • Chaudhary P.
        • Marshall T.I.
        • Perozziello F.M.
        • et al.
        Relative biological effectiveness variation along monoenergetic and modulated Bragg peaks of a 62-MeV therapeutic proton beam: A preclinical assessment.
        Int J Radiat Oncol Biol Phys. 2014; 90: 27-35
        • Calugaru V.
        • Nauraye C.
        • Noel G.
        • et al.
        Radiobiological characterization of two therapeutic proton beams with different initial energy spectra used at the Institut Curie Proton Therapy Center in Orsay.
        Int J Radiat Oncol Biol Phys. 2011; 81: 1136-1143
        • Britten R.A.
        • Nazaryan V.
        • Davis L.K.
        • et al.
        Variations in the RBE for cell killing along the depth-dose profile of a modulated proton therapy beam.
        Radiat Res. 2013; 179: 21-28

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.